Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAPGEF4 | Q8WZA2 | 2/20 | 0.52 |
| ▸ | STK17A | Q9UEE5 | 3/20 | 0.46 |
| ▸ | AXL | P30530 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.44 |
| ▸ | BRD4 | O60885 | 7/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | BCDIN3D | Q7Z5W3 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL264236 | 0.89 | RAPGEF4 (0.52) | RAPGEF4STK17AAXLEGFRKDR | |
| SCHEMBL12279058 | 0.87 | GRM4 (0.48) | STK17AAXLEGFRKDRBRD4 | |
| SCHEMBL12279148 | 0.87 | STK17A (0.53) | RAPGEF4STK17AAXLEGFRKDR | |
| SCHEMBL17915940 | 0.85 | STK17A (0.51) | RAPGEF4STK17AAXLBRD4JAK1 | |
| SCHEMBL270203 | 0.82 | BRD4 (0.49) | RAPGEF4STK17AAXLBRD4JAK1 | |
| SCHEMBL303841 | 0.82 | BCL6 (0.60) | RAPGEF4STK17AAXLBRD4JAK1 | |
| SCHEMBL12279478 | 0.81 | BRD4 (0.59) | EGFRKDRBRD4JAK1JAK3 | |
| SCHEMBL12279725 | 0.79 | STK17A (0.52) | STK17AEGFRKDRBRD4AURKA | |
| SCHEMBL12279486 | 0.78 | PIK3CA (0.52) | EGFRKDRBRD4JAK1JAK3 | |
| SCHEMBL12813342 | 0.77 | STK17A (0.57) | RAPGEF4STK17AAXLEGFRKDR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | RAPGEF4 2982/4885STK17A 243/4885AXL 267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.